Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With Cancer – High Grade Gliomas
A randomized trial involving adult patients diagnosed with a high-grade glioma, no history of substance abuse, liver or kidney damage or myocardial infarction were eligible for inclusion in a tolerability study on two different ratios of medicinal cannabis.
Participants were on average 53.3 years old.
• from baseline to week 12 found that the 1:1 ratio favoured both physical (p=0.025) and functional (p=0.014) capacity and improved sleep (p=0.009).
• Analysis of changes from baseline to week 12 also found ;
11% of 61 participants had a reduction in disease
34% were stable
16% had slight enhancement
10% had progressive disease.
No serious adverse events occurred. Side effects included dry mouth, tiredness at night, dizziness, drowsiness.
The investigational product consisted of two standardised and quality-assured specially formulated oil-based organic WHOLE PLANT EXTRACTS of CANNABIS based on :
1:1 THC 4.6mg/ml:CBD 4.8mg/ml
4:1 THC 15mg/ml:CBD 3.8mg/ml
This study demonstrated that a single nightly dose of THC-containing medicinal cannabis was safe, had no serious adverse effects and was well tolerated in patients. Medicinal cannabis significantly improved sleep, functional wellbeing, and quality of life.
The post A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Whole Plant Extracts of Cannabis in Cancer appeared first on I Am Billy.
